FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2413478001> ?p ?o ?g. }

• W2413478001 startingPage "939" @default.
• W2413478001 abstract "BACKGROUND It is the main choice that neoadjust chemotherapy following surgery and induction chemotherapy following radiation therapy for locally advanced lung cancer. The aim of this study is to explore the selection of operation or synchronous radiotherapy and chemotherapy for stage III non small cell lung cancer (NSCLC) after induction chemotherapy. METHODS After two cycles of induction chemotherapy, patients with stage III NSCLC were divided at random into synchronous radiotherapy and chemotherapy group or operation therapy group for therapy by the chemotherapy effect PR or CR, or estimated complete excision; and patients accepting complete excision operation continuously accepted two cycles of chemotherapy according to original proposal. RESULTS Total 71 patients with stage III NSCLC entered therapy group after induction chemotherapy. Where, 37 patients accepted synchronous radiotherapy and chemotherapy, and 34 patients accepted operation. The 1-year, 2-year, and 3-year survival rate of synchronous radiotherapy and chemotherapy group was 78.4%, 40.5% and 23.4% respectively, while that of operation group was 81.1%, 39.5% and 35.1% respectively. The medium survival of the two groups was 18.0+/-2.4 and 23.0+/-1.6 respectively, and there was no statistical difference (P=0.23) in survival rate. The disease-free survival rate of synchronous radiotherapy and chemotherapy group and operation group was 14.0+/-1.7 months and 19.0+/-3.2 months respectively (P=0.044), and obviously, there was statistical difference. CONCLUSIONS After induction chemotherapy, patients with stage III NSCLC could select operation therapy and synchronous radiotherapy and chemotherapy. Where, synchronous radiotherapy and chemotherapy is relatively safe, but the adverse reaction can't be ignored. Operation therapy has higher risk and difficulty for induction chemotherapy, but has shown its superiority in disease-free survival." @default.
• W2413478001 created "2016-06-24" @default.
• W2413478001 creator A5047585931 @default.
• W2413478001 creator A5058194639 @default.
• W2413478001 creator A5073606490 @default.
• W2413478001 creator A5078020955 @default.
• W2413478001 creator A5089443281 @default.
• W2413478001 date "2009-08-20" @default.
• W2413478001 modified "2023-09-27" @default.
• W2413478001 title "Selection of Therapy Method for Stage III Non Small Cell Lung Cancer after Induction Chemotherapy." @default.
• W2413478001 doi "https://doi.org/10.3779/j.issn.1009-3419.2009.08.23" @default.
• W2413478001 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20719187" @default.
• W2413478001 hasPublicationYear "2009" @default.
• W2413478001 type Work @default.
• W2413478001 sameAs 2413478001 @default.
• W2413478001 citedByCount "0" @default.
• W2413478001 crossrefType "journal-article" @default.
• W2413478001 hasAuthorship W2413478001A5047585931 @default.
• W2413478001 hasAuthorship W2413478001A5058194639 @default.
• W2413478001 hasAuthorship W2413478001A5073606490 @default.
• W2413478001 hasAuthorship W2413478001A5078020955 @default.
• W2413478001 hasAuthorship W2413478001A5089443281 @default.
• W2413478001 hasConcept C121608353 @default.
• W2413478001 hasConcept C126322002 @default.
• W2413478001 hasConcept C141071460 @default.
• W2413478001 hasConcept C143998085 @default.
• W2413478001 hasConcept C146357865 @default.
• W2413478001 hasConcept C151730666 @default.
• W2413478001 hasConcept C2776256026 @default.
• W2413478001 hasConcept C2776611710 @default.
• W2413478001 hasConcept C2776694085 @default.
• W2413478001 hasConcept C509974204 @default.
• W2413478001 hasConcept C71924100 @default.
• W2413478001 hasConcept C86803240 @default.
• W2413478001 hasConceptScore W2413478001C121608353 @default.
• W2413478001 hasConceptScore W2413478001C126322002 @default.
• W2413478001 hasConceptScore W2413478001C141071460 @default.
• W2413478001 hasConceptScore W2413478001C143998085 @default.
• W2413478001 hasConceptScore W2413478001C146357865 @default.
• W2413478001 hasConceptScore W2413478001C151730666 @default.
• W2413478001 hasConceptScore W2413478001C2776256026 @default.
• W2413478001 hasConceptScore W2413478001C2776611710 @default.
• W2413478001 hasConceptScore W2413478001C2776694085 @default.
• W2413478001 hasConceptScore W2413478001C509974204 @default.
• W2413478001 hasConceptScore W2413478001C71924100 @default.
• W2413478001 hasConceptScore W2413478001C86803240 @default.
• W2413478001 hasIssue "8" @default.
• W2413478001 hasLocation W24134780011 @default.
• W2413478001 hasLocation W24134780012 @default.
• W2413478001 hasOpenAccess W2413478001 @default.
• W2413478001 hasPrimaryLocation W24134780011 @default.
• W2413478001 hasVolume "12" @default.
• W2413478001 isParatext "false" @default.
• W2413478001 isRetracted "false" @default.
• W2413478001 magId "2413478001" @default.
• W2413478001 workType "article" @default.